Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARNCOMBI
2021-002174-52Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of tozinameran and elasomeran in coronavirus disease 2019 (COVID-19), sponsored by Assistance publique - Hôpitaux de Paris. Started May 2021; status: completed.
02
Drugs
tozinameranelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-002174-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002174-52.